IDYA
IDEAYA Biosciences, Inc. · Healthcare
32.34
1.22%(-0.40)
Prev. Close35.80
10.70%(+3.46)
Pre-marketLast Updated: — ET
52W L: $13.4552W H: $39.28
$32.50
CHG-0.78 (-2.34%)
H$35.89
L$29.57
VOL14M
IDYA (1h)
IDEAYA Biosciences, Inc. · Healthcare
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) was the target of unusually large options trading on Monday. Stock investors acquired 24,287 call options on the stock. This represents an increase of 2,391% compared to the typical volume of 975 call options. IDEAYA Biosciences Stock Performance IDEAYA Biosciences stock opened at $32.34 on Tuesday. The
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogs KAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX models Multiple combination opportunities with IDE574 and IDEAYA's proprietary pipeline Potential first-in-class and best-in-class preclinical profile will be presented at AACR 2026 SOUTH SAN FRANCISCO, Calif., April 6, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 dose escalation trial evaluating IDE574, a potential first-in-class oral small molecule equipotent dual inhibitor of the lysine acetyltransferase (KAT) 6 and 7 paralogs, both of which have been shown to support cancer cell survival.
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs in multiple preclinical models IDE849 Phase 1 study advancing globally to determine RP2D, including current dose evaluation at 3.5 mg/kg IV Q3W.
SOUTH SAN FRANCISCO, Calif., March 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 26, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 49,000 shares of the Company's common stock to two newly hired employees.
SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events and provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have given a buy rating to
Stein Jeffrey
director
50,000 SH @ $32.96
2026-03-02
Bleharski Joshua
officer: Chief Financial Officer
170,000 SH @ $32.19
2026-01-30
WHITE MICHAEL ANTHONY
officer: Chief Scientific Officer
190,000 SH @ $32.19
2026-01-30
Beaupre Darrin
officer: Chief Medical Officer
175,000 SH @ $32.19
2026-01-30
DORMAN STUART
officer: Chief Commercial Officer
155,000 SH @ $32.19
2026-01-30
Hata Yujiro S
director, officer: President and CEO
600,000 SH @ $32.19
2026-01-30
Snyder Douglas B.
officer: SVP, General Counsel
130,000 SH @ $32.19
2026-01-30
Snyder Douglas B.
officer: SVP, General Counsel
1,041 SH @ $16.91
2025-11-28